Table 2.
Compound | SARS-CoV-2 Pseudovirus Entry Inhibition (%) | Compound | SARS-CoV-2 Pseudovirus Entry Inhibition (%) |
---|---|---|---|
Baicalin, µM | Baicalein, µM | ||
30 | −3.3 | 30 | 14.6 |
10 | −6.6 | 10 | 3.9 |
3.3 | −11.9 | 3.3 | −1.9 |
1.1 | −12.1 | 1.1 | −2 |
Compound | SARS-CoV-2 Pseudovirus Entry Inhibition (%) | Compound | SARS-CoV-2 Pseudovirus Entry Inhibition (%) |
---|---|---|---|
Baicalin, µM | Baicalein, µM | ||
30 | −3.3 | 30 | 14.6 |
10 | −6.6 | 10 | 3.9 |
3.3 | −11.9 | 3.3 | −1.9 |
1.1 | −12.1 | 1.1 | −2 |